Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Pyrroles. Found 11 abstracts

Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018 Apr 05;378(14):1277-90.   PMCID: PMC5972549
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16.   PMCID: PMC4878938
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50.   PMCID: 4175044
Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene. 2012 Mar 08;31(10):1217-27.   PMCID: PMC3204164
Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, Li T, Ross EA, Oseni S, Fargnoli J, Jordan VC. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer. 2010 Jun;46(9):1537-53.   PMCID: PMC2927957
von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?. Oncology (Williston Park). 2009 Jan;23(1):65-6.   PMCID: PMC 2861343
Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92.   PMCID: PMC2448846
Wetherbee SL. New weapons to snuff out kidney cancer. Nursing. 2006 Dec;36(12 Pt.1):58-63; quiz 64.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Pyrroles

Pyrroles Indoles Renal Cell Carcinoma therapeutic use drug therapy Kidney Neoplasms Antineoplastic Agents Female administration & dosage Pyrimidines Angiogenesis Inhibitors genetics Disease-Free Survival Male pathology Middle Aged therapy analogs & derivatives metabolism Nephrectomy methods adverse effects drug effects Phenylurea Compounds Tumor Cell Line Adjuvant Chemotherapy surgery Gastrointestinal Stromal Tumors Apoptosis Neoplasm Metastasis mortality Organ Sparing Treatments Piperazines pharmacology Nephrons Drug Administration Schedule Niacinamide Double-Blind Method Carcinogenesis antagonists & inhibitors Adult Survival Rate Vascular Endothelial Growth Factor A Disease Progression Sulfonamides Aged Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Protein Kinase Inhibitors Thiazoles Alanine Neoplasm Transplantation Von Hippel-Lindau Tumor Suppressor Protein Sorafenib src-Family Kinases Postoperative Care Mutation Pyrazoles Platelet-Derived Growth Factor alpha Receptor Ipilimumab Quality of Life blood Sunitinib Fibroblast Growth Factor Receptor-Type 1 physiology Drug Dose-Response Relationship nursing Neoplasm Antigens inhibitors Gene Amplification Survival Analysis Risk Factors Immunotherapy enzymology pharmacokinetics Small Interfering RNA Vascular Endothelial Growth Factor Receptor-2 Matrix Metalloproteinase 2 80 and over Aged Immunological Antineoplastic Agents secondary Signal Transduction Breast Neoplasms IGF Type 1 Receptor Mitogen-Activated Protein Kinase Kinases Neoplasm Staging Pyridines Clinical Trials as Topic Mice antagonists & Antitumor Drug Screening Assays Cell Proliferation Immunohistochemistry Drug Monitoring Tumor Biomarkers Cell Adhesion Nude Mice Follow-Up Studies Angiopoietin-2 Vascular Endothelial Growth Factor Receptor-3 Reverse Transcriptase Polymerase Chain Reaction Gene Silencing Single Nucleotide Polymorphism Triazines Protein-Serine-Threonine Kinases Proto-Oncogene Proteins c-kit Phosphorylation Mitosis Neoplastic Gene Expression Regulation Oral Administration Monoclonal Antibodies Neoadjuvant Therapy Random Allocation Heterologous Transplantation alpha Subunit Hypoxia-Inducible Factor 1 Prognosis Risk Tamoxifen DNA Mutational Analysis Carbonic Anhydrases Proto-Oncogene Proteins c-akt Benzenesulfonates
Last updated on Friday, January 03, 2020